recombinant antithrombin (ATryn)
Jump to navigation
Jump to search
Indications
- hereditary antithrombin deficiency
- prevention of peri-operative & peri-partum thromboembolism
- treatment of established DVT
Contraindications
- not indicated for treatment of thromboembolic events in the absence of hereditary antithrombin deficiency
Mechanism of action
More general terms
More specific terms
References
- ↑ Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015